VRTX Stock Risk & Deep Value Analysis
Vertex Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About VRTX Stock
We analyzed Vertex Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran VRTX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
VRTX Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is a major pipeline setback, particularly the failure of a late-stage asset like VX-548 or significant delays/failures in the Type 1 Diabetes program, which could dramatically impact future growth prospects and valuation. Given the market's high expectations for these programs, such an event could lead to a 20-30%+ stock price correction.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Insider selling of $37.9M over the last three months, though not a major proportion of market cap, indicates some profit-taking.
- ⚠
The significant market capitalization inherently limits the realistic 10x growth potential within the specified 3-5 year timeframe for a pharmaceutical company.
- ⚠
Reliance on continued successful R&D and regulatory approvals to sustain growth beyond the CF franchise.
Upcoming Risk Events
- 📅
Clinical trial failures or delays for key pipeline assets (e.g., VX-548, T1D programs)
- 📅
Unexpected competition in new therapeutic areas
- 📅
Regulatory setbacks or rejections
When to Reconsider
- 🚪
Major clinical trial failure for a pivotal pipeline asset (e.g., Phase 3 for VX-548).
- 🚪
FDA/EMA regulatory rejection for a key drug candidate.
- 🚪
Significant deceleration in overall revenue growth below 5% year-over-year for two consecutive quarters.
Unlock VRTX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Vertex Pharmaceuticals Inc (VRTX) Do?
Market Cap
$109.04B
Sector
Healthcare
Industry
Biotechnology
Employees
6,100
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Visit Vertex Pharmaceuticals Inc WebsiteInvestment Thesis
Vertex Pharmaceuticals presents a compelling investment opportunity due to its foundational dominance in the high-margin Cystic Fibrosis market and a transformative pipeline that leverages cutting-edge science in gene editing, non-opioid pain, and Type 1 Diabetes. These future growth drivers, supported by strong financials and proven execution, position Vertex for sustained long-term growth and potential market leadership in novel therapeutic areas, despite the challenging 10x target from its current large valuation.
Is VRTX Stock Undervalued?
Unlock the full AI analysis for VRTX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
VRTX Price Targets & Strategy
12-Month Target
$555.00
Bull Case
$595.00
Bear Case
$425.00
Valuation Basis
Based on analyst consensus target, which implies approximately 32.6x FY2026 EPS estimate of $17.00.
Entry Strategy
Consider dollar-cost averaging on dips towards the $400-$420 range, which aligns with recent support levels.
Exit Strategy
Take partial profits at $550-$560, and place a stop-loss order if the stock breaks below $400 on a sustained basis.
Portfolio Allocation
4-6% for a moderate-risk biotech allocation.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is VRTX Financially Healthy?
Valuation
P/E Ratio
27.58
Forward P/E
23.36
EV/EBITDA
26.97
PEG Ratio
2.30
Price/Book
6.90
Price/Sales
10.37
Profitability
Gross Margin
86.24%
Operating Margin
34.77%
Net Margin
32.94%
Return on Equity
22.70%
Revenue Growth
8.90%
EPS
$15.33
Balance Sheet
Current Ratio
2.90
Quick Ratio
2.27
Debt/Equity
0.01
Total Debt
$8.40B
Cash & Equivalents
$3.50B
Cash Flow
Operating Cash Flow
$3.80B
Free Cash Flow
$3.20B
EBITDA
$4.40B
Other
Beta (Volatility)
0.31
Does VRTX Have a Competitive Moat?
Sign in to unlockMoat Rating
🏰 Wide
Moat Trend
Expanding
Moat Sources
3 Identified
Vertex's moat is durable due to its strong patent portfolio and regulatory exclusivity in the CF market. Its expansion into complex new modalities like gene editing and cell therapies with significant R&D investment creates further intellectual property and high barriers to entry, making it difficult for competitors to replicate its success.
Moat Erosion Risks
- •Expiration of key CF patents in the distant future, although new generation drugs are in development.
- •Emergence of a superior gene editing or cell therapy technology from a competitor.
- •Clinical trial failures or regulatory rejections for pipeline assets could limit future moat expansion.
VRTX Competitive Moat Analysis
Sign up to see competitive advantages
VRTX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bullish, driven by excitement over pipeline developments, particularly in gene editing and non-opioid pain.
Institutional Sentiment
Positive, indicated by 'Moderate Buy' analyst consensus, recent upgrade from Wolfe Research, and high institutional ownership (90.96%).
Insider Activity (Form 4)
Insiders sold 80,431 shares worth $37.9M over the last three months, with an average transaction price of approximately $487.65 for one noted transaction.
Options Flow
Normal options activity, no specific unusual institutional positioning noted in the provided intelligence.
Earnings Intelligence
Next Earnings
2026-05-04
Surprise Probability
Medium, as Q4 2025 revenue beat estimates but EPS slightly missed, suggesting mixed predictability.
Historical Earnings Pattern
Vertex often experiences significant price movement around pipeline updates and regulatory news, alongside financial performance and future guidance. Earnings beats with strong guidance typically lead to rallies.
Key Metrics to Watch
Competitive Position
Top Competitor
CRSP (CRISPR Therapeutics)
Market Share Trend
Maintaining dominant market share in CF while actively gaining ground in emerging therapeutic areas such as gene editing (with Casgevy) and poised to enter the non-opioid pain market.
Valuation vs Peers
Vertex trades at a premium to many diversified large-cap pharma companies (e.g., Amgen, Gilead) on a P/E basis, reflecting its higher growth profile and robust pipeline. Its trailing P/E of 27.8 is reasonable for a leading growth biotech but high for a general pharmaceutical. Companies like CRISPR Therapeutics are often pre-profit, making P/E comparisons difficult.
Competitive Advantages
- •Extensive and dominant intellectual property (IP) in Cystic Fibrosis treatments.
- •Strong R&D capabilities and expertise in developing novel small molecules and cell/gene therapies.
- •Established global commercial infrastructure and regulatory expertise.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive VRTX Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings (May 4, 2026)
- •Continued commercial ramp-up of Casgevy
- •Further pipeline updates on VX-548 (non-opioid pain) regulatory filings
Medium-Term (6-18 months)
- •Regulatory decisions/approvals for VX-548 (mid-to-late 2026)
- •Advancement of Type 1 Diabetes cell therapy programs (clinical trial data)
- •Potential new indications or market expansions for existing CF therapies
Long-Term (18+ months)
- •Broad commercialization success of gene editing portfolio across multiple indications
- •Disruption in pain management with non-opioid therapies
- •Expansion into new therapeutic areas beyond current pipeline
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for VRTX?
- ✓
Positive Phase 3 trial results and regulatory approval for VX-548.
- ✓
Breakthrough clinical data for the Type 1 Diabetes program.
- ✓
Successful integration and commercial expansion of Casgevy beyond current indications.
Bull Case Analysis
See what could go right with Premium
Competing with VRTX
See how Vertex Pharmaceuticals Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Vertex Pharmaceuticals Inc VRTX | $109.0B | 4.7 | 27.6 | $12.0B | 32.9% | 8.9% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Vertex Pharmaceuticals Inc Makes Money
Vertex Pharmaceuticals discovers, develops, and commercializes innovative medicines for serious diseases. Its primary revenue currently comes from its portfolio of highly effective treatments for Cystic Fibrosis (CF). The company invests heavily in research and development to expand its pipeline into other challenging diseases, aiming to bring new therapies to market and generate revenue through drug sales and licensing agreements.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Vertex Pharmaceuticals Inc (VRTX)?
As of April 29, 2026, Vertex Pharmaceuticals Inc has a DVR Score of 4.7 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Vertex Pharmaceuticals Inc?
Vertex Pharmaceuticals Inc's market capitalization is approximately $109.0B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Vertex Pharmaceuticals Inc use?
VRTX is the ticker symbol for Vertex Pharmaceuticals Inc. The company trades on the NMS.
What is the risk level for VRTX stock?
Our analysis rates Vertex Pharmaceuticals Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of VRTX?
Vertex Pharmaceuticals Inc currently has a price-to-earnings (P/E) ratio of 27.6. This is in line with broader market averages.
Is Vertex Pharmaceuticals Inc's revenue growing?
Vertex Pharmaceuticals Inc has reported revenue growth of 8.9%. The company is growing at a moderate pace.
Is VRTX stock profitable?
Vertex Pharmaceuticals Inc has a profit margin of 32.9%. This indicates strong profitability.
How often is the VRTX DVR analysis updated?
Our AI-powered analysis of Vertex Pharmaceuticals Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 29, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for VRTX (Vertex Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.